AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.69 USD | +40.84% |
|
+120.15% | -29.40% |
| Apr. 12 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 12 | Sector Update: Health Care | MT |
Presenter SpeechSurani Fernando (Attendees)Hi, everyone. I'm Surani Fernando, your moderator f...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.69
USD
Average target price
88.75
USD
Spread / Average Target
+659.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.40% | 245M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- AGEN Stock
- News Agenus Inc.
- Transcript : Agenus Inc. - Special Call
